Ocular toxoplasmosis past, present and new aspects of an old disease

Progress in Retinal and Eye Research

Volumn 39, Issue , 2014, Pages 77-106

  Maenz, M ^a   Schluter D ^b   Liesenfeld, O ^a   Schares, G ^c   Gross, U ^d   Pleyer, U ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Ocular toxoplasmosis; Retinochoroiditis; Toxoplasma gondii; Uveitis

Indexed keywords

OCULAR TOXOPLASMOSIS; RETINOCHOROIDITIS; TOXOPLASMA GONDII; UVEITIS;

ANTIPROTOZOAL AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; RISK FACTORS; TOXOPLASMA; TOXOPLASMOSIS, OCULAR;

EID: 84893815504     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2013.12.005     Document Type: Review

References (358)

1. Ajzenberg D., Cogne N., Paris L., Bessieres M.H., Thulliez P., Filisetti D., Pelloux H., Marty P., Darde M.L. Genotype of 86 Toxoplasma gondii isolates associated with human congenital toxoplasmosis, and correlation with clinical findings. J.Infect. Dis. 2002, 186:684-689.
2. Ajzenberg D., Yera H., Marty P., Paris L., Dalle F., Menotti J., Aubert D., Franck J., Bessieres M.H., Quinio D., Pelloux H., Delhaes L., Desbois N., Thulliez P., Robert-Gangneux F., Kauffmann-Lacroix C., Pujol S., Rabodonirina M., Bougnoux M.E., Cuisenier B., Duhamel C., Duong T.H., Filisetti D., Flori P., Gay-Andrieu F., Pratlong F., Nevez G., Totet A., Carme B., Bonnabau H., Darde M.L., Villena I. Genotype of 88 Toxoplasma gondii isolates associated with toxoplasmosis in immunocompromised patients and correlation with clinical findings. J.Infect. Dis. 2009, 199:1155-1167.
3. Ajzenberg D. Type I strains in human toxoplasmosis: myth or reality?. Future Microbiol. 2010, 5:841-843.
4. Albuquerque M.C., Aleixo A.L., Benchimol E.I., Leandro A.C., das Neves L.B., Vicente R.T., Bonecini-Almeida Mda G., Amendoeira M.R. The IFN-gamma+874T/A gene polymorphism is associated with retinochoroiditis toxoplasmosis susceptibility. Mem. Inst. Oswaldo Cruz 2009, 104:451-455.
5. Aouizerate F., Cazenave J., Poirier L., Verin P., Cheyrou A., Begueret J., Lagoutte F. Detection of Toxoplasma gondii in aqueous humour by the polymerase chain reaction. Br. J. Ophthalmol. 1993, 77:107-109.
6. Asatova M.M., Avdiukhina T.I., Gobunova Iu P. The results of a serological examination of the population for toxoplasmosis and the estimated incidences of congenital toxoplasmosis in 2 foci in Uzbekistan. Med. Parazitol. Mosk. 1993, 25-27.
7. Ashrafunnessa, Khatun S., Islam M.N., Huq T. Seroprevalence of toxoplasma antibodies among the antenatal population in Bangladesh. J.Obstet. Gynaecol. Res. 1998, 24:115-119.
8. Aspinall T.V., Guy E.C., Roberts K.E., Joynson D.H., Hyde J.E., Sims P.F. Molecular evidence for multiple Toxoplasma gondii infections in individual patients in England and Wales: public health implications. Int. J. Parasitol. 2003, 33:97-103.
9. Baharivand N., Mahdavifard A., Fouladi R.F. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial. Int. Ophthalmol. 2013, 33(1):39-46.
10. Bahia-Oliveira L.M., Jones J.L., Azevedo-Silva J., Alves C.C., Orefice F., Addiss D.G. Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg. Infect. Dis. 2003, 9:55-62.
11. Balansard B., Bodaghi B., Cassoux N., Fardeau C., Romand S., Rozenberg F., Rao N.A., Lehoang P. Necrotising retinopathies simulating acute retinal necrosis syndrome. Br. J. Ophthalmol. 2005, 89:96-101.
12. Basu S., Biswas J., Pleyer U., Pathangay A., Manohar Babu B. An ophthalmologist survey-based study of the atypical presentations and current treatment practices of ocular toxoplasmosis in India. J.Parasit. Dis. 2011, 35:148-154.
13. Beghetto E., Spadoni A., Bruno L., Buffolano W., Gargano N. Chimeric antigens of Toxoplasma gondii: toward standardization of toxoplasmosis serodiagnosis using recombinant products. J.Clin. Microbiol. 2006, 44:2133-2140.
14. Benevento J.D., Jager R.D., Noble A.G., Latkany P., Mieler W.F., Sautter M., Meyers S., Mets M., Grassi M.A., Rabiah P., Boyer K., Swisher C., McLeod R., Toxoplasmosis Study G. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch. Ophthalmol. 2008, 126:1152-1156.
15. Bidgoli S., Koch P., Caspers L. Toxoplasmic chorioretinitis: positive PCR on vitreous with negative serology for Toxoplasma gondii. J.Fr. Ophtalmol. 2011, 34(384):e381-385.
16. Boothroyd J.C., Grigg M.E. Population biology of Toxoplasma gondii and its relevance to human infection: do different strains cause different disease?. Curr. Opin. Microbiol. 2002, 5:438-442.
17. Bosch-Driessen E.H., Rothova A. Recurrent ocular disease in postnatally acquired toxoplasmosis. Am. J. Ophthalmol. 1999, 128:421-425.
18. Bosch-Driessen L.E., Berendschot T.T., Ongkosuwito J.V., Rothova A. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology 2002, 109:869-878.
19. Bou G., Figueroa M.S., Marti-Belda P., Navas E., Guerrero A. Value of PCR for detection of Toxoplasma gondii in aqueous humor and blood samples from immunocompetent patients with ocular toxoplasmosis. J.Clin. Microbiol. 1999, 37:3465-3468.
20. Bowie W.R., King A.S., Werker D.H., Isaac-Renton J.L., Bell A., Eng S.B., Marion S.A. Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet 1997, 350:173-177.
21. Boyer K., Hill D., Mui E., Wroblewski K., Karrison T., Dubey J.P., Sautter M., Noble A.G., Withers S., Swisher C., Heydemann P., Hosten T., Babiarz J., Lee D., Meier P., McLeod R. Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin. Infect. Dis. 2011, 53:1081-1089.
22. Boyle J.P., Rajasekar B., Saeij J.P., Ajioka J.W., Berriman M., Paulsen I., Roos D.S., Sibley L.D., White M.W., Boothroyd J.C. Just one cross appears capable of dramatically altering the population biology of a eukaryotic pathogen like Toxoplasma gondii. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10514-10519.
23. Brown C.R., McLeod R. Class I MHC genes and CD8+ T cells determine cyst number in Toxoplasma gondii infection. J.Immunol. 1990, 145:3438-3441.
24. Burnett A.J., Shortt S.G., Isaac-Renton J., King A., Werker D., Bowie W.R. Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak. Ophthalmology 1998, 105:1032-1037.
25. Buxton D., Innes E.A. A commercial vaccine for ovine toxoplasmosis. Parasitology 110 Suppl. 1995, S11-6.
26. Carneiro A.C., Andrade G.M., Costa J.G., Pinheiro B.V., Vasconcelos-Santos D.V., Ferreira A.M., Su C., Januario J.N., Vitor R.W. Genetic characterization of Toxoplasma gondii revealed highly diverse genotypes for isolates from newborns with congenital toxoplasmosis in Southeastern Brazil. J.Clin. Microbiol. 2013, 51:901-907.
27. Caspi R.R. Experimental autoimmune uveoretinitis in the rat and mouse. Curr. Protoc. Immunol. 2003, Chapter 15, Unit 15 16.
28. Caspi R.R., Silver P.B., Luger D., Tang J., Cortes L.M., Pennesi G., Mattapallil M.J., Chan C.C. Mouse models of experimental autoimmune uveitis. Ophthalmic Res. 2008, 40:169-174.
29. Chai J.-Y., Lin A., Shin E.-H., Oh M.-D., Han E.-T., Nam H.-W., Lee S.-H. Laboratory passage and characterization of an isolate of Toxoplasma gondii from an ocular patient in Korea. Kor. J. Parasitol. 2003, 41:147-154.
30. Chapey E., Wallon M., Debize G., Rabilloud M., Peyron F. Diagnosis of congenital toxoplasmosis by using a whole-blood gamma interferon release assay. J.Clin. Microbiol. 2010, 48:41-45.
31. Charles E., Callegan M.C., Blader I.J. The SAG1 Toxoplasma gondii surface protein is not required for acute ocular toxoplasmosis in mice. Infect. Immun. 2007, 75:2079-2083.
32. Charles E., Joshi S., Ash J.D., Fox B.A., Farris A.D., Bzik D.J., Lang M.L., Blader I.J. CD4 T-cell suppression by cells from Toxoplasma gondii-infected retinas is mediated by surface protein PD-L1. Infect. Immun. 2010, 78:3484-3492.
33. Chumpitazi B.F., Bouillet L., Fricker-Hidalgo H., Lacharme T., Romanet J.P., Massot C., Chiquet C., Pelloux H. Contribution of anti-Hsp70.1 IgG antibody levels to the diagnostic certainty of clinically suspected ocular toxoplasmosis. Invest Ophthalmol. Vis. Sci. 2010, 51:5530-5536.
34. Chung H., Kim J.G., Choi S.H., Lee S.Y., Yoon Y.H. Bilateral toxoplasma retinochoroiditis simulating cytomegalovirus retinitis in an allogeneic bone marrow transplant patient. Korean J. Ophthalmol. 2008, 22:197-200.
35. Contini C., Seraceni S., Cultrera R., Incorvaia C., Sebastiani A., Picot S. Evaluation of a Real-time PCR-based assay using the lightcycler system for detection of Toxoplasma gondii bradyzoite genes in blood specimens from patients with toxoplasmic retinochoroiditis. Int. J. Parasitol. 2005, 35:275-283.
36. Contini C. Clinical and diagnostic management of toxoplasmosis in the immunocompromised patient. Parassitologia 2008, 50:45-50.
37. Cook A.J., Gilbert R.E., Buffolano W., Zufferey J., Petersen E., Jenum P.A., Foulon W., Semprini A.E., Dunn D.T. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis. BMJ 2000, 321:142-147.
38. Cordeiro C.A., Moreira P.R., Bessa T.F., Costa G.C., Dutra W.O., Campos W.R., Orefice F., Young L.H., Teixeira A.L. Interleukin-6 gene polymorphism (-174 G/C) is associated with toxoplasmic retinochoroiditis. Acta Ophthalmol. 2013, 91:e311-314.
39. Couper K.N., Nielsen H.V., Petersen E., Roberts F., Roberts C.W., Alexander J. DNA vaccination with the immunodominant tachyzoite surface antigen (SAG-1) protects against adult acquired Toxoplasma gondii infection but does not prevent maternofoetal transmission. Vaccine 2003, 21:2813-2820.
40. Courret N., Darche S., Sonigo P., Milon G., Buzoni-Gatel D., Tardieux I. CD11c- and CD11b-expressing mouse leukocytes transport single Toxoplasma gondii tachyzoites to the brain. Blood 2006, 107:309-316.
41. Couvreur J., Thulliez P., Daffos F., Aufrant C., Bompard Y., Gesquiere A., Desmonts G. In utero treatment of toxoplasmic fetopathy with the combination pyrimethamine-sulfadiazine. Fetal Diagn. Ther. 1993, 8:45-50.
42. Cozon G.J., Ferrandiz J., Nebhi H., Wallon M., Peyron F. Estimation of the avidity of immunoglobulin G for routine diagnosis of chronic Toxoplasma gondii infection in pregnant women. Eur. J. Clin. Microbiol. Infect. Dis. 1998, 17:32-36.
43. Culbertson W.W., Tabbara K.F., O'Connor R. Experimental ocular toxoplasmosis in primates. Arch. Ophthalmol. 1982, 100:321-323.
44. Davidson M.G., Lappin M.R., English R.V., Tompkins M.B. Afeline model of ocular toxoplasmosis. Invest Ophthalmol. Vis. Sci. 1993, 34:3653-3660.
45. Davidson M.G., Lappin M.R., Rottman J.R., Tompkins M.B., English R.V., Bruce A.T., Jayawickrama J. Paradoxical effect of clindamycin in experimental, acute toxoplasmosis in cats. Antimicrob. Agents Chemother. 1996, 40:1352-1359.
46. de-la-Torre A., Rios-Cadavid A.C., Cardozo-Garcia C.M., Gomez-Marin J.E. Frequency and factors associated with recurrences of ocular toxoplasmosis in a referral centre in Colombia. Br. J. Ophthalmol. 2009, 93:1001-1004.
47. De Groot-Mijnes J.D., Rothova A., Van Loon A.M., Schuller M., Ten Dam-Van Loon N.H., De Boer J.H., Schuurman R., Weersink A.J. Polymerase chain reaction and Goldmann-Witmer coefficient analysis are complimentary for the diagnosis of infectious uveitis. Am. J. Ophthalmol. 2006, 141:313-318.
48. de Moura L., Bahia-Oliveira L.M., Wada M.Y., Jones J.L., Tuboi S.H., Carmo E.H., Ramalho W.M., Camargo N.J., Trevisan R., Graca R.M., da Silva A.J., Moura I., Dubey J.P., Garrett D.O. Waterborne toxoplasmosis, Brazil, from field to gene. Emerg. Infect. Dis. 2006, 12:326-329.
49. de Souza E.C., Casella A.M. Clinical and tomographic features of macular punctate outer retinal toxoplasmosis. Arch. Ophthalmol. 2009, 127:1390-1394.
50. Delair E., Monnet D., Grabar S., Dupouy-Camet J., Yera H., Brezin A.P. Respective roles of acquired and congenital infections in presumed ocular toxoplasmosis. Am. J. Ophthalmol. 2008, 146:851-855.
51. Delair E., Creuzet C., Dupouy-Camet J., Roisin M.P. Invitro effect of TNF-alpha and IFN-gamma in retinal cell infection with Toxoplasma gondii. Invest Ophthalmol. Vis. Sci. 2009, 50:1754-1760.
52. Dellacasa-Lindberg I., Hitziger N., Barragan A. Localized recrudescence of Toxoplasma infections in the central nervous system of immunocompromised mice assessed by invivo bioluminescence imaging. Microbes Infect. 2007, 9:1291-1298.
53. Demarco A.L., Rodrigues Mde L., Figueiredo J.F., Deghaide N.H., de Menezes M.B., Demarco L.A., Fernandes A.P., Donadi E.A. Susceptibility to toxoplasmic retinochoroiditis is associated with HLA alleles reported to be implicated with rapid progression to AIDS. Dis. Markers 2012, 33:309-312.
54. Denkers E.Y., Gazzinelli R.T. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin. Microbiol. Rev. 1998, 11:569-588.
55. Derouin F., Pelloux H. Prevention of toxoplasmosis in transplant patients. Clin. Microbiol. Infect. 2008, 14:1089-1101.
56. Diamond J. Evolution, consequences and future of plant and animal domestication. Nature 2002, 418:700-707.
57. Dodds E.M., Holland G.N., Stanford M.R., Yu F., Siu W.O., Shah K.H., Ten Dam-van Loon N., Muccioli C., Hovakimyan A., Barisani-Asenbauer T. Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination. Am. J. Ophthalmol. 2008, 146:856-865. e852.
58. Doft B.H., Gass D.M. Punctate outer retinal toxoplasmosis. Arch. Ophthalmol. 1985, 103:1332-1336.
59. dos Santos T.R., Nunes C.M., Luvizotto M.C., de Moura A.B., Lopes W.D., da Costa A.J., Bresciani K.D. Detection of Toxoplasma gondii oocysts in environmental samples from public schools. Vet. Parasitol. 2010, 171:53-57.
60. Drogemuller K., Helmuth U., Brunn A., Sakowicz-Burkiewicz M., Gutmann D.H., Mueller W., Deckert M., Schlüter D. Astrocyte gp130 expression is critical for the control of Toxoplasma encephalitis. J.Immunol. 2008, 181:2683-2693.
61. Dubey J., Kotula A., Sharar A., Andrews C., Lindsay D. Effect of high temperature on infectivity of Toxoplasma gondii tissue cysts in pork. J.Parasitol. 1990, 201-204.
62. Dubey J.P., Sharma S.P., Juranek D.D., Sulzer A.J., Teutsch S.M. Characterization of Toxoplasma gondii isolates from an outbreak of toxoplasmosis in Atlanta, Georgia. Am. J. Vet. Res. 1981, 42:1007-1010.
63. Dubey J.P., Graham D.H., Blackston C.R., Lehmann T., Gennari S.M., Ragozo A.M., Nishi S.M., Shen S.K., Kwok O.C., Hill D.E., Thulliez P. Biological and genetic characterisation of Toxoplasma gondii isolates from chickens (Gallus domesticus) from Sao Paulo, Brazil: unexpected findings. Int. J. Parasitol. 2002, 32:99-105.
64. Dubey J.P., Jones J.L. Toxoplasma gondii infection in humans and animals in the United States. Int. J. Parasitol. 2008, 38:1257-1278.
65. Dubey J.P., Lago E.G., Gennari S.M., Su C., Jones J.L. Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology. Parasitology 2012, 139:1375-1424.
66. Dubremetz J.F., Lebrun M. Virulence factors of Toxoplasma gondii. Microbes Infect. 2012, 14(15):1403-1410.
67. Dukaczewska A.K. Establishment of a Murine Model of Ocular Toxoplasmosis 2012, 78. Medical Faculty. FU, Berlin, Germany.
68. Dumetre A., Le Bras C., Baffet M., Meneceur P., Dubey J.P., Derouin F., Duguet J.P., Joyeux M., Moulin L. Effects of ozone and ultraviolet radiation treatments on the infectivity of Toxoplasma gondii oocysts. Vet. Parasitol. 2008, 153:209-213.
69. Dunay I.R., Chan W.C., Haynes R.K., Sibley L.D. Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model. Antimicrob. Agents Chemother. 2009, 53:4450-4456.
70. Dunn D., Wallon M., Peyron F., Petersen E., Peckham C., Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet 1999, 353:1829-1833.
71. Dutra M.S., Bela S.R., Peixoto-Rangel A.L., Fakiola M., Cruz A.G., Gazzinelli A., Quites H.F., Bahia-Oliveira L.M., Peixe R.G., Campos W.R., Higino-Rocha A.C., Miller N.E., Blackwell J.M., Antonelli L.R., Gazzinelli R.T. Association of a NOD2 gene polymorphism and T-helper 17 cells with presumed ocular toxoplasmosis. J.Infect. Dis. 2013, 207:152-163.
72. Dutton G.N., McMenamin P.G., Hay J., Cameron S. The ultrastructural pathology of congenital murine toxoplasmic retinochoroiditis. Part II: the morphology of the inflammatory changes. Exp. Eye Res. 1986, 43:545-560.
73. Eckert G.U., Melamed J., Menegaz B. Optic nerve changes in ocular toxoplasmosis. Eye (Lond.) 2007, 21:746-751.
74. Elbez-Rubinstein A., Ajzenberg D., Darde M.L., Cohen R., Dumetre A., Yera H., Gondon E., Janaud J.C., Thulliez P. Congenital toxoplasmosis and reinfection during pregnancy: case report, strain characterization, experimental model of reinfection, and review. J.Infect. Dis. 2009, 199:280-285.
75. Elmore S.A., Jones J.L., Conrad P.A., Patton S., Lindsay D.S., Dubey J.P. Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention. Trends Parasitol. 2010, 26:190.
76. Elshout M., Erckens R.J., Webers C.A., Beckers H.J., Berendschot T.T., de Brabander J., Hendrikse F., Schouten J.S. Detection of Raman spectra in ocular drugs for potential invivo application of Raman spectroscopy. J.Ocul. Pharmacol. Ther. 2011, 27:445-451.
77. Errera M.H., Goldschmidt P., Batellier L., Degorge S., Heron E., Laroche L., Sahel J.A., Westcott M., Chaumeil C. Real-time polymerase chain reaction and intraocular antibody production for the diagnosis of viral versus toxoplasmic infectious posterior uveitis. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249:1837-1846.
78. Escoffier P., Jeanny J.C., Marinach-Patrice C., Jonet L., Raoul W., Behar-Cohen F., Paris L., Danis M., Dubremetz J.F., Mazier D. Toxoplasma gondii: flat-mounting of retina as a new tool for the observation of ocular infection in mice. Exp. Parasitol. 2010, 126:259-262.
79. Eyles D.E., Coleman N. Antibiotics in the treatment of toxoplasmosis. Am. J. Trop. Med. Hyg. 1953, 2:64-69.
80. Eyles D.E., Coleman N. The relative activity of the common sulfonamides against experimental toxoplasmosis in the mouse. Am. J. Trop. Med. Hyg. 1953, 2:54-63.
81. Fachado A., Rodriguez A., Angel S.O., Pinto D.C., Vila I., Acosta A., Amendoeira R.R., Lannes-Vieira J. Protective effect of a naked DNA vaccine cocktail against lethal toxoplasmosis in mice. Vaccine 2003, 21:1327-1335.
82. Fardeau C., Romand S., Rao N.A., Cassoux N., Bettembourg O., Thulliez P., Lehoang P. Diagnosis of toxoplasmic retinochoroiditis with atypical clinical features. Am. J. Ophthalmol. 2002, 134:196-203.
83. Fatoohi F., Cozon G.J., Wallon M., Kodjikian L., Peyron F. Systemic T cell response to Toxoplasma gondii antigen in patients with ocular toxoplasmosis. Jpn. J. Ophthalmol. 2006, 50:103-110.
84. Faucher B., Garcia-Meric P., Franck J., Minodier P., Francois P., Gonnet S., L'Ollivier C., Piarroux R. Long-term ocular outcome in congenital toxoplasmosis: a prospective cohort of treated children. J.Infect. 2012, 64:104-109.
85. Fekkar A., Bodaghi B., Touafek F., Le Hoang P., Mazier D., Paris L. Comparison of immunoblotting, calculation of the Goldmann-Witmer coefficient, and real-time PCR using aqueous humor samples for diagnosis of ocular toxoplasmosis. J.Clin. Microbiol. 2008, 46:1965-1967.
86. Ferreira M.U., Hiramoto R.M., Aureliano D.P., da Silva-Nunes M., da Silva N.S., Malafronte R.S., Muniz P.T. Acommunity-based survey of human toxoplasmosis in rural Amazonia: seroprevalence, seroconversion rate, and associated risk factors. Am. J. Trop. Med. Hyg. 2009, 81:171-176.
87. Feustel S.M., Meissner M., Liesenfeld O. Toxoplasma gondii and the blood-brain barrier. Virulence 2012, 3:182-192.
88. Fish R.H., Hoskins J.C., Kline L.B. Toxoplasmosis neuroretinitis. Ophthalmology 1993, 100:1177-1182.
89. Freeman K., Tan H.K., Prusa A., Petersen E., Buffolano W., Malm G., Cortina-Borja M., Gilbert R. Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study. Pediatrics 2008, 121:e1215-e1222.
90. Frenkel J.K., Pfefferkorn E.R., Smith D.D., Fishback J.L. Prospective vaccine prepared from a new mutant of Toxoplasma gondii for use in cats. Am. J. Vet. Res. 1991 May, 52(5):759-763.
91. Friedmann C.T., Knox D.L. Variations in recurrent active toxoplasmic retinochoroiditis. Arch. Ophthalmol. 1969, 81:481-493.
92. Friedrich R., Simon H.U., Muller W.A., Sych F.J. Ocular toxoplasmosis: the role of cellular immune defense in the development of recurrences. Results from animal experiments. Ger. J. Ophthalmol. 1992, 1:54-57.
93. Fujiwara T., Machida S., Hasegawa Y., Tazawa Y. Punctate outer retinal toxoplasmosis with multiple choroidal neovascularizations. Retina 2006, 26:360-362.
94. Furtado J.M., Bharadwaj A.S., Ashander L.M., Olivas A., Smith J.R. Migration of Toxoplasma gondii-infected dendritic cells across human retinal vascular endothelium. Invest Ophthalmol. Vis. Sci. 2012, 53:6856-6862.
95. Furtado J.M., Bharadwaj A.S., Chipps T.J., Pan Y., Ashander L.M., Smith J.R. Toxoplasma gondii tachyzoites cross retinal endothelium assisted by intercellular adhesion molecule-1 invitro. Immunol. Cell. Biol. 2012, 90:912-915.
96. Furtado J.M., Ashander L.M., Mohs K., Chipps T.J., Appukuttan B., Smith J.R. Toxoplasma gondii migration within and infection of human retina. PLoS One 2013, 8:e54358.
97. Garcia-Meric P., Franck J., Dumon H., Piarroux R. Management of congenital toxoplasmosis in France: current data. Presse Med. 2010, 39:530-538.
98. Garweg J., Boehnke M., Koerner F. Restricted applicability of the polymerase chain reaction for the diagnosis of ocular toxoplasmosis. Ger. J. Ophthalmol. 1996, 5:104-108.
99. Garweg J.G., Kuenzli H., Boehnke M. Experimental ocular toxoplasmosis in naive and primed rabbits. Ophthalmologica 1998, 212:136-141.
100. Garweg J.G., Jacquier P., Boehnke M. Early aqueous humor analysis in patients with human ocular toxoplasmosis. J.Clin. Microbiol. 2000, 38:996-1001.
101. Garweg J.G., Scherrer J., Wallon M., Kodjikian L., Peyron F. Reactivation of ocular toxoplasmosis during pregnancy. BJOG 2005, 112:241-242.
102. Garweg J.G., Ventura A.C., Halberstadt M., Silveira C., Muccioli C., Belfort R.J., Jacquier P. Specific antibody levels in the aqueous humor and serum of two distinct populations of patients with ocular toxoplasmosis. Int. J. Med. Microbiol. 2005, 295:287-295.
103. Garweg J.G., Boehnke M. The antibody response in experimental ocular toxoplasmosis. Graefes Arch. Clin. Exp. Ophthalmol. 2006, 244:1668-1679.
104. Garweg J.G., Scherrer J.N., Halberstadt M. Recurrence characteristics in European patients with ocular toxoplasmosis. Br. J. Ophthalmol. 2008, 92:1253-1256.
105. Garweg J.G., Stanford M.R. Therapy for ocular toxoplasmosis-the future. Ocul. Immunol. Inflamm. 2013, 21:300-305.
106. Gazzinelli R., Xu Y., Hieny S., Cheever A., Sher A. Simultaneous depletion of CD4+ and CD8+ T lymphocytes is required to reactivate chronic infection with Toxoplasma gondii. J.Immunol. 1992, 149:175-180.
107. Gazzinelli R.T., Brezin A., Li Q., Nussenblatt R.B., Chan C.C. Toxoplasma gondii: acquired ocular toxoplasmosis in the murine model, protective role of TNF-alpha and IFN-gamma. Exp. Parasitol. 1994, 78:217-229.
108. Gazzinelli R.T., Wysocka M., Hayashi S., Denkers E.Y., Hieny S., Caspar P., Trinchieri G., Sher A. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii. J.Immunol. 1994, 153:2533-2543.
109. Gilbert R., Dezateux C. Newborn screening for congenital toxoplasmosis: feasible, but benefits are not established. Arch. Dis. Child. 2006, 91:629-631.
110. Gilbert R.E., Dunn D.T., Lightman S., Murray P.I., Pavesio C.E., Gormley P.D., Masters J., Parker S.P., Stanford M.R. Incidence of symptomatic toxoplasma eye disease: aetiology and public health implications. Epidemiol. Infect. 1999, 123:283-289.
111. Gilbert R.E., Stanford M.R. Is ocular toxoplasmosis caused by prenatal or postnatal infection?. Br. J. Ophthalmol. 2000, 84:224-226.
112. Gilbert R.E., Freeman K., Lago E.G., Bahia-Oliveira L.M., Tan H.K., Wallon M., Buffolano W., Stanford M.R., Petersen E. Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe. PLoS Neglect. Trop. Dis. 2008, 2:e277.
113. Glasner P.D., Silveira C., Kruszon-Moran D., Martins M.C., Burnier Junior M., Silveira S., Camargo M.E., Nussenblatt R.B., Kaslow R.A., Belfort Junior R. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am. J. Ophthalmol. 1992, 114:136-144.
114. Goldenberg D., Goldstein M., Loewenstein A., Habot-Wilner Z. Vitreal, retinal, and choroidal findings in active and scarred toxoplasmosis lesions: a prospective study by spectral-domain optical coherence tomography. Gr. Arch. Clin. Exp. Ophthalmol. 2013, 251:2037-2045.
115. Goldmann H., Witmer R. Antibodies in the aqueous humor. Ophthalmologica 1954, 127:323-330.
116. Golkar M., Azadmanesh K., Khalili G., Khoshkholgh-Sima B., Babaie J., Mercier C., Brenier-Pinchart M.P., Fricker-Hidalgo H., Pelloux H., Cesbron-Delauw M.F. Serodiagnosis of recently acquired Toxoplasma gondii infection in pregnant women using enzyme-linked immunosorbent assays with a recombinant dense granule GRA6 protein. Diagn. Microbiol. Infect. Dis. 2008, 61:31-39.
117. Goncalves R.M., Rodrigues D.H., Camargos da Costa A.M., Teixeira M.M., Ribeiro Campos W., Orefice F., Teixeira A.L. Increased serum levels of CXCL8 chemokine in acute toxoplasmic retinochoroiditis. Acta Ophthalmol. Scand. 2007, 85:871-876.
118. Gormley P.D., Pavesio C.E., Minnasian D., Lightman S. Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease. Invest Ophthalmol. Vis. Sci. 1998, 39:1171-1175.
119. Grant I.H., Gold J.W., Rosenblum M., Niedzwiecki D., Armstrong D. Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS 1990, 4:519-521.
120. Grigg M.E., Bonnefoy S., Hehl A.B., Suzuki Y., Boothroyd J.C. Success and virulence in Toxoplasma as the result of sexual recombination between two distinct ancestries. Science 2001, 294:161-165.
121. Grigg M.E., Ganatra J., Boothroyd J.C., Margolis T.P. Unusual abundance of atypical strains associated with human ocular toxoplasmosis. J.Infect. Dis. 2001, 184:633-639.
122. Gross U. Prevalence and public-health-aspects of toxoplasmosis. Bundesgesundheitsblatt Gesundheitsforsch. Gesundheitsschutz 2004, 47:692-697.
123. Guerina N.G. Congenital infection with Toxoplasma gondii. Pediatr. Ann. 1994, 23(138-142):147-151.
124. Halos L., Thébault A., Aubert D., Thomas M., Perret C., Geers R., Alliot A., Escotte-Binet S., Ajzenberg D., Dardé M.-L. An innovative survey underlining the significant level of contamination by Toxoplasma gondii of ovine meat consumed in France. Int. J. Parasitol. 2010, 40:193-200.
125. Harning D., Spenter J., Metsis A., Vuust J., Petersen E. Recombinant Toxoplasma gondii surface antigen 1 (P30) expressed in Escherichia coli is recognized by human Toxoplasma-specific immunoglobulin M (IgM) and IgG antibodies. Clin. Diagn Lab. Immunol. 1996, 3:355-357.
126. Hay J., Lee W.R., Dutton G.N., Hutchison W.M., Siim J.C. Congenital toxoplasmic retinochoroiditis in a mouse model. Ann. Trop. Med. Parasitol. 1984, 78:109-116.
127. Hazirolan D., Pleyer U. Think Global-Act Local: intravitreal drug delivery systems in chronic noninfectious uveitis. Ophthal. Res. 2012, 49:59-65.
128. Hencken C.P., Jones-Brando L., Bordon C., Stohler R., Mott B.T., Yolken R., Posner G.H., Woodard L.E. Thiazole, oxadiazole, and carboxamide derivatives of artemisinin are highly selective and potent inhibitors of Toxoplasma gondii. J.Med. Chem. 2010, 53:3594-3601.
129. Herrmann D.C., Barwald A., Maksimov A., Pantchev N., Vrhovec M.G., Conraths F.J., Schares G. Toxoplasma gondii sexual cross in a single naturally infected feline host: generation of highly mouse-virulent and avirulent clones, genotypically different from clonal types I, II and III. Vet. Res. 2012, 43:39.
130. Hill D., Coss C., Dubey J.P., Wroblewski K., Sautter M., Hosten T., Munoz-Zanzi C., Mui E., Withers S., Boyer K., Hermes G., Coyne J., Jagdis F., Burnett A., McLeod P., Morton H., Robinson D., McLeod R. Identification of a sporozoite-specific antigen from Toxoplasma gondii. J.Parasitol. 2011, 97:328-337.
131. Ho-Yen D.O., Joss A.W., Balfour A.H., Smyth E.T., Baird D., Chatterton J.M. Use of the polymerase chain reaction to detect Toxoplasma gondii in human blood samples. J.Clin. Pathol. 1992, 45:910-913.
132. Hofhuis A., van Pelt W., van Duynhoven Y.T., Nijhuis C.D., Mollema L., van der Klis F.R., Havelaar A.H., Kortbeek L.M. Decreased prevalence and age-specific risk factors for Toxoplasma gondii IgG antibodies in The Netherlands between 1995/1996 and 2006/2007. Epidemiol. Infect. 2011, 139:530-538.
133. Hogan M.J. Toxoplasmosis; ocular manifestations. Trans. Am. Acad. Ophthalmol. Otolaryngol. 1950, 54:183-189.
134. Hogan M.J. Ocular Toxoplasmosis 1951, Columbia Univ. Press.
135. Hogan M.J. Ocular toxoplasmosis; clinical and laboratory diagnosis; evaluation of immunologic tests; treatment. AMA Arch. Ophthalmol. 1956, 55:333-345.
136. Hogan M.J., Kimura S.J., Lewis A., Zweigart P.A. Early and delayed ocu lar manifestations of congenital toxoplasmosis. Trans. Am. Ophthalmol. Soc. 1957, 55:275-293. Discussion 293-276.
137. Hogan M.J. Ocular toxoplasmosis. Am. J. Ophthalmol. 1958, 46:467-494.
138. Hogan M.J. Ocular toxoplasmosis. Trans. Am. Acad. Ophthalmol. Otolaryngol. 1958, 62:7-37.
139. Hogan M.J., Zweigart P.A., Lewis A. Experimental ocular toxoplasmosis. II. AMA Arch. Ophthalmol. 1958, 60:448-449.
140. Hogan M.J., Kimura S.J., O'Connor G.R. Ocular toxoplasmosis. Arch. Ophthalmol. 1964, 72:592-600.
141. Holec-Gasior L., Ferra B., Drapala D., Lautenbach D., Kur J. Anew MIC1-MAG1 recombinant chimeric antigen can be used instead of the Toxoplasma gondii lysate antigen in serodiagnosis of human toxoplasmosis. Clin. Vaccine Immunol. 2012, 19:57-63.
142. Holland G.N., Engstrom R.E., Glasgow B.J., Berger B.B., Daniels S.A., Sidikaro Y., Harmon J.A., Fischer D.H., Boyer D.S., Rao N.A., et al. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am. J. Ophthalmol. 1988, 106:653-667.
143. Holland G.N., O'Connor G.R., Diaz R.F., Minasi P., Wara W.M. Ocular toxoplasmosis in immunosuppressed nonhuman primates. Invest Ophthalmol. Vis. Sci. 1988, 29:835-842.
144. Holland G.N. Ocular toxoplasmosis in the immunocompromised host. Int. Ophthalmol. 1989, 13:399-402.
145. Holland G.N., Cornell P.J., Park M.S., Barbetti A., Yuge J., Kreiger A.E., Kaplan H.J., Pepose J.S., Heckenlively J.R., Culbertson W.W., et al. An association between acute retinal necrosis syndrome and HLA-DQw7 and phenotype Bw62, DR4. Am. J. Ophthalmol. 1989, 108:370-374.
146. Holland G.N., Lewis K.G. An update on current practices in the management of ocular toxoplasmosis. Am. J. Ophthalmol. 2002, 134:102-114.
147. Holland G.N. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am. J. Ophthalmol. 2003, 136:973-988.
148. Holland G.N. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am. J. Ophthalmol. 2004, 137:1-17.
149. Holland G.N., Crespi C.M., ten Dam-van Loon N., Charonis A.C., Yu F., Bosch-Driessen L.H., Rothova A. Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. Am. J. Ophthalmol. 2008, 145:1007-1013.
150. Hovakimyan A., Cunningham E.T. Ocular toxoplasmosis. Ophthalmol. Clin. North Am. 2002, 15:327-332.
151. Hruzik A., Asif A.R., Gross U. Identification of Toxoplasma gondii SUB1 antigen as a marker for acute infection by use of an innovative evaluation method. J.Clin. Microbiol. 2011, 49:2419-2425.
152. Hu M.S., Schwartzman J.D., Yeaman G.R., Collins J., Seguin R., Khan I.A., Kasper L.H. Fas-FasL interaction involved in pathogenesis of ocular toxoplasmosis in mice. Infect. Immun. 1999, 67:928-935.
153. Innes E.A., Bartley P.M., Buxton D., Katzer F. Ovine toxoplasmosis. Parasitology 2009, 136:1887-1894.
154. Jacquier P., Hohlfeld P., Vorkauf H., Zuber P. Epidemiology of toxoplasmosis in Switzerland: national study of seroprevalence monitored in pregnant women 1990-1991. Schweiz Med. Wochenschr Suppl. 1995, 65:29S-38S.
155. Jakob E., Reuland M.S., Mackensen F., Harsch N., Fleckenstein M., Lorenz H.M., Max R., Becker M.D. Uveitis subtypes in a german interdisciplinary uveitis center-analysis of 1916 patients. J.Rheumatol. 2009, 36:127-136.
156. Jamieson S.E., de Roubaix L.A., Cortina-Borja M., Tan H.K., Mui E.J., Cordell H.J., Kirisits M.J., Miller E.N., Peacock C.S., Hargrave A.C., Coyne J.J., Boyer K., Bessieres M.H., Buffolano W., Ferret N., Franck J., Kieffer F., Meier P., Nowakowska D.E., Paul M., Peyron F., Stray-Pedersen B., Prusa A.R., Thulliez P., Wallon M., Petersen E., McLeod R., Gilbert R.E., Blackwell J.M. Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One 2008, 3:e2285.
157. Jamieson S.E., Cordell H., Petersen E., McLeod R., Gilbert R.E., Blackwell J.M. Host genetic and epigenetic factors in toxoplasmosis. Mem. Inst. Oswaldo Cruz 2009, 104:162-169.
158. Jamieson S.E., Peixoto-Rangel A.L., Hargrave A.C., Roubaix L.A., Mui E.J., Boulter N.R., Miller E.N., Fuller S.J., Wiley J.S., Castellucci L., Boyer K., Peixe R.G., Kirisits M.J., Elias Lde S., Coyne J.J., Correa-Oliveira R., Sautter M., Smith N.C., Lees M.P., Swisher C.N., Heydemann P., Noble A.G., Patel D., Bardo D., Burrowes D., McLone D., Roizen N., Withers S., Bahia-Oliveira L.M., McLeod R., Blackwell J.M. Evidence for associations between the purinergic receptor P2X(7) (P2RX7) and toxoplasmosis. Genes. Immun. 2010, 11:374-383.
159. Janku J. Pathogenesa a pathologická anatomie tak nazvaneho vrozeného kolombu žluté skvrany voku normálné velikem a microphthalmickém s nalezem parasitu v sítnici. Cas. Lek. Ceskyck 1923, 62. 1021-1027, 1054-1059, 1081-1085, 1111-1115, 1138-1143.
160. Jasper S., Vedula S.S., John S.S., Horo S., Sepah Y.J., Nguyen Q.D. Corticosteroids for ocular toxoplasmosis. Cochrane Database Syst. Rev. 2013, 4:CD007417.
161. Jensen E. Retino-chorioiditis juxtapapillaris. Arch. F. Ophthal. 1908, 69:41-46.
162. Jia X., Hu M., Wang C., Wang C., Zhang F., Han Q., Zhao R., Huang Q., Xu H., Yuan H., Ren H. Coordinated gene expression of Th17- and Treg-associated molecules correlated with resolution of the monophasic experimental autoimmune uveitis. Mol. Vis. 2011, 17:1493-1507.
163. John B., Ricart B., Tait Wojno E.D., Harris T.H., Randall L.M., Christian D.A., Gregg B., De Almeida D.M., Weninger W., Hammer D.A., Hunter C.A. Analysis of behavior and trafficking of dendritic cells within the brain during toxoplasmic encephalitis. PLoS Pathog. 2011, 7:e1002246.
164. Johnson A.M. Strain-dependent, route of challenge-dependent, murine susceptibility to toxoplasmosis. ZParasitenkd. 1984, 70:303-309.
165. Johnson S.M., Murphy R.C., Geiger J.A., DeRocher A.E., Zhang Z., Ojo K.K., Larson E.T., Perera B.G., Dale E.J., He P., Reid M.C., Fox A.M., Mueller N.R., Merritt E.A., Fan E., Parsons M., Van Voorhis W.C., Maly D.J. Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity. J.Med. Chem. 2012, 55:2416-2426.
166. Jones J.L., Kruszon-Moran D., Sanders-Lewis K., Wilson M. Toxoplasma gondii infection in the United States, 1999 2004, decline from the prior decade. Am. J. Trop. Med. Hyg. 2007, 77:405-410.
167. Jones J.L., Dargelas V., Roberts J., Press C., Remington J.S., Montoya J.G. Risk factors for Toxoplasma gondii infection in the United States. Clin. Infect. Dis. 2009, 49:878-884.
168. Jones J.L., Dubey J.P. Waterborne toxoplasmosis-recent developments. Exp. Parasitol. 2010, 124:10.
169. Jongert E., Melkebeek V., De Craeye S., Dewit J., Verhelst D., Cox E. An enhanced GRA1-GRA7 cocktail DNA vaccine primes anti-Toxoplasma immune responses in pigs. Vaccine 2008, 26:1025-1031.
170. Kahloun R., Mbarek S., Khairallah-Ksiaa I., Jelliti B., Yahia S.B., Khairallah M. Branch retinal artery occlusion associated with posterior uveitis. J.Ophthal. Inflamm. Infect. 2013, 3:16.
171. Kamani J., Mani A.U., Egwu G.O., Kumshe H.A. Seroprevalence of human infection with Toxoplasma gondii and the associated risk factors, in Maiduguri, Borno state, Nigeria. Ann. Trop. Med. Parasitol. 2009, 103:317-321.
172. Kapperud G., Jenum P.A., Stray-Pedersen B., Melby K.K., Eskild A., Eng J. Risk factors for Toxoplasma gondii infection in pregnancy. Results of a prospective case-control study in Norway. Am. J. Epidemiol. 1996, 144:405-412.
173. Kawanokuchi J., Shimizu K., Nitta A., Yamada K., Mizuno T., Takeuchi H., Suzumura A. Production and functions of IL-17 in microglia. J.Neuroimmunol. 2008, 194:54-61.
174. Khan A., Bohme U., Kelly K.A., Adlem E., Brooks K., Simmonds M., Mungall K., Quail M.A., Arrowsmith C., Chillingworth T., Churcher C., Harris D., Collins M., Fosker N., Fraser A., Hance Z., Jagels K., Moule S., Murphy L., O'Neil S., Rajandream M.A., Saunders D., Seeger K., Whitehead S., Mayr T., Xuan X., Watanabe J., Suzuki Y., Wakaguri H., Sugano S., Sugimoto C., Paulsen I., Mackey A.J., Roos D.S., Hall N., Berriman M., Barrell B., Sibley L.D., Ajioka J.W. Common inheritance of chromosome Ia associated with clonal expansion of Toxoplasma gondii. Genome Res. 2006, 16:1119-1125.
175. Khan A., Fux B., Su C., Dubey J.P., Darde M.L., Ajioka J.W., Rosenthal B.M., Sibley L.D. Recent transcontinental sweep of Toxoplasma gondii driven by a single monomorphic chromosome. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14872-14877.
176. Khan A., Dubey J.P., Su C., Ajioka J.W., Rosenthal B.M., Sibley L.D. Genetic analyses of atypical Toxoplasma gondii strains reveal a fourth clonal lineage in North America. Int. J. Parasitol. 2011, 41:645-655.
177. Khan A., Miller N., Roos D.S., Dubey J.P., Ajzenberg D., Darde M.L., Ajioka J.W., Rosenthal B., Sibley L.D. Amonomorphic haplotype of chromosome Ia is associated with widespread success in clonal and nonclonal populations of Toxoplasma gondii. MBio 2011, 2:e00228-00211.
178. Khan I.A., Schwartzman J.D., Matsuura T., Kasper L.H. Adichotomous role for nitric oxide during acute Toxoplasma gondii infection in mice. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13955-13960.
179. Kieffer F., Wallon M., Garcia P., Thulliez P., Peyron F., Franck J. Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis. Pediatric Infect. Dis. J. 2008, 27:27-32.
180. Kijlstra A., Jongert E. Toxoplasma-safe meat: close to reality?. Trends Parasitol. 2009, 25:18-22.
181. Kikumura A., Ishikawa T., Norose K. Kinetic analysis of cytokines, chemokines, chemokine receptors and adhesion molecules in murine ocular toxoplasmosis. Br. J. Ophthalmol. 2012, 96:1259-1267.
182. Kishore K., Conway M.D., Peyman G.A. Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. Ophthalmic Surg. Lasers 2001, 32:183-192.
183. Kistiah K., Frean J., Winiecka-Krusnell J., Barragan A. Unexpectedly low seroprevalence of toxoplasmosis in South Africa. Onderstepoort J. Vet. Res. 2012, 79:E1.
184. Kodjikian L., Wallon M., Fleury J., Denis P., Binquet C., Peyron F., Garweg J.G. Ocular manifestations in congenital toxoplasmosis. Gr. Arch. Clin. Exp. Ophthalmol. 2006, 244:14-21.
185. Kong J.T., Grigg M.E., Uyetake L., Parmley S., Boothroyd J.C. Serotyping of Toxoplasma gondii infections in humans using synthetic peptides. J.Infect. Dis. 2003, 187:1484-1495.
186. Koppe J.G., Loewer-Sieger D.H., de Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet 1986, 1:254-256.
187. Kortagere S. Screening for small molecule inhibitors of Toxoplasma gondii. Expert Opin. Drug. Discov. 2012, 1-14.
188. Kotula A., Dubey J., Sharar A., Andrews C., Shen S., Lindsay D. Effect of freezing on infectivity of Toxoplasma gondii tissue cysts in pork. J.Food Prot. 1991, 54.
189. Labalette P., Delhaes L., Margaron F., Fortier B., Rouland J.F. Ocular toxoplasmosis after the fifth decade. Am. J. Ophthalmol. 2002, 133:506-515.
190. Lachenmaier S.M., Deli M.A., Meissner M., Liesenfeld O. Intracellular transport of Toxoplasma gondii through the blood-brain barrier. J.Neuroimmunol. 2011, 232:119-130.
191. Lakhanpal V., Schocket S.S., Nirankari V.S. Clindamycin in the treatment of toxoplasmic retinochoroiditis. Am. J. Ophthalmol. 1983, 95:605-613.
192. Lasave A.F., Diaz-Llopis M., Muccioli C., Belfort R., Arevalo J.F. Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months. Ophthalmology 2010, 117:1831-1838.
193. Li S., Galvan G., Araujo F.G., Suzuki Y., Remington J.S., Parmley S. Serodiagnosis of recently acquired Toxoplasma gondii infection using an enzyme-linked immunosorbent assay with a combination of recombinant antigens. Clin. Diagn Lab. Immunol. 2000, 7:781-787.
194. Lim H., Lee S.E., Jung B.K., Kim M.K., Lee M.Y., Nam H.W., Shin J.G., Yun C.H., Cho H.I., Shin E.H., Chai J.Y. Serologic survey of toxoplasmosis in Seoul and Jeju-do, and a brief review of its seroprevalence in Korea. Korean J. Parasitol. 2012, 50:287-293.
195. London N.J., Hovakimyan A., Cubillan L.D., Siverio C.D., Cunningham E.T. Prevalence, clinical characteristics, and causes of vision loss in patients with ocular toxoplasmosis. Eur. J. Ophthalmol. 2011, 21:811-819.
196. Lopes A.P., Dubey J.P., Moutinho O., Gargate M.J., Vilares A., Rodrigues M., Cardoso L. Seroepidemiology of Toxoplasma gondii infection in women from the North of Portugal in their childbearing years. Epidemiol. Infect. 2012, 140:872-877.
197. Lovett J.L., Sibley L.D. Intracellular calcium stores in Toxoplasma gondii govern invasion of host cells. J.Cell. Sci. 2003, 116:3009-3016.
198. Lu F., Huang S., Kasper L.H. Interleukin-10 and pathogenesis of murine ocular toxoplasmosis. Infect. Immun. 2003, 71:7159-7163.
199. Lu F., Huang S., Kasper L.H. CD4+ T cells in the pathogenesis of murine ocular toxoplasmosis. Infect. Immun. 2004, 72:4966-4972.
200. Lu F., Huang S., Hu M.S., Kasper L.H. Experimental ocular toxoplasmosis in genetically susceptible and resistant mice. Infect. Immun. 2005, 73:5160-5165.
201. Lu F., Huang S., Kasper L.H. The temperature-sensitive mutants of Toxoplasma gondii and ocular toxoplasmosis. Vaccine 2009, 27:573-580.
202. Luft B.J., Remington J.S. Toxoplasmic encephalitis in AIDS. Clin. Infect. Dis. 1992, 15:211-222.
203. Lynch L.F., Lynch M.I., Ferreira R.S., Vasconcelos M.S., Melo N., Ferreira S., Malagueno E. Ocular toxoplasmosis: evaluation of lacrimal-specific secretory IgA levels in both patients with active and inactive phases of the disease. Mem. Inst. Oswaldo Cruz 2011, 106:625-628.
204. Lynch M.I., Malagueno E., Lynch L.F., Ferreira S., Stheling R., Orefice F. Anti-Toxoplasma gondii secretory IgA in tears of patients with ocular toxoplasmosis: immunodiagnostic validation by ELISA. Mem. Inst. Oswaldo Cruz 2009, 104:818-822.
205. Lyons R.E., McLeod R., Roberts C.W. Toxoplasma gondii tachyzoite-bradyzoite interconversion. Trends Parasitol. 2002, 18:198-201.
206. Mack D.G., Johnson J.J., Roberts F., Roberts C.W., Estes R.G., David C., Grumet F.C., McLeod R. HLA-class II genes modify outcome of Toxoplasma gondii infection. Int. J. Parasitol. 1999, 29:1351-1358.
207. Maksimov P., Zerweck J., Maksimov A., Hotop A., Gross U., Pleyer U., Spekker K., Daubener W., Werdermann S., Niederstrasser O., Petri E., Mertens M., Ulrich R.G., Conraths F.J., Schares G. Peptide microarray analysis of in silico-predicted epitopes for serological diagnosis of Toxoplasma gondii infection in humans. Clin. Vaccine Immunol. 2012, 19:865-874.
208. Mamidi A., DeSimone J.A., Pomerantz R.J. Central nervous system infections in individuals with HIV-1 infection. J.Neurovirol. 2002, 8:158-167.
209. Manschot W.A., Daamen C.B. Connatal ocular toxoplasmosis. Arch. Ophthalmol. 1965, 74:48-54.
210. Marcolino P.T., Silva D.A., Leser P.G., Camargo M.E., Mineo J.R. Molecular markers in acute and chronic phases of human toxoplasmosis: determination of immunoglobulin G avidity by Western blotting. Clin. Diagn Lab. Immunol. 2000, 7:384-389.
211. McFadden D.C., Camps M., Boothroyd J.C. Resistance as a tool in the study of old and new drug targets in Toxoplasma. Drug. Resist. Updat. 2001, 4:79-84.
212. McLeod R., Brown C., Mack D. Immunogenetics influence outcome of Toxoplasma gondii infection. Res. Immunol. 1993, 144:61-65.
213. McLeod R., Boyer K.M., Lee D., Mui E., Wroblewski K., Karrison T., Noble A.G., Withers S., Swisher C.N., Heydemann P.T., Sautter M., Babiarz J., Rabiah P., Meier P., Grigg M.E. Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009). Clin. Infect. Dis. 2012, 54:1595-1605.
214. McMaster P.R., Powers K.G., Finerty J.F., Lunde M.N. The effect of two chlorinated lincomycin analogues against acute toxoplasmosis in mice. Am. J. Trop. Med. Hyg. 1973, 22:14-17.
215. McMenamin P.G., Dutton G.N., Hay J., Cameron S. The ultrastructural pathology of congenital murine toxoplasmic retinochoroiditis. Part I: the localization and morphology of Toxoplasma cysts in the retina. Exp. Eye Res. 1986, 43:529-543.
216. Meenken C., Assies J., van Nieuwenhuizen O., Holwerda-van der Maat W.G., van Schooneveld M.J., Delleman W.J., Kinds G., Rothova A. Long term ocular and neurological involvement in severe congenital toxoplasmosis. Br. J. Ophthalmol. 1995, 79:581-584.
217. Meenken C., Rothova A., de Waal L.P., van der Horst A.R., Mesman B.J., Kijlstra A. HLA typing in congenital toxoplasmosis. Br. J. Ophthalmol. 1995, 79:494-497.
218. Meerburg B.G., Kijlstra A. Changing climate-changing pathogens: Toxoplasma gondii in North-Western Europe. Parasitol. Res. 2009, 105:17-24.
219. Melamed J., Eckert G.U., Spadoni V.S., Lago E.G., Uberti F. Ocular manifestations of congenital toxoplasmosis. Eye (Lond.) 2010, 24:528-534.
220. Mercier A., Devillard S., Ngoubangoye B., Bonnabau H., Banuls A.L., Durand P., Salle B., Ajzenberg D., Darde M.L. Additional haplogroups of Toxoplasma gondii out of Africa: population structure and mouse-virulence of strains from Gabon. PLoS Negl. Trop. Dis. 2010, 4:e876.
221. Mets M.B., Holfels E., Boyer K.M., Swisher C.N., Roizen N., Stein L., Stein M., Hopkins J., Withers S., Mack D., Luciano R., Patel D., Remington J.S., Meier P., McLeod R. Eye manifestations of congenital toxoplasmosis. Am. J. Ophthalmol. 1996, 122:309-324.
222. Mevelec M.N., Bout D., Desolme B., Marchand H., Magne R., Bruneel O., Buzoni-Gatel D. Evaluation of protective effect of DNA vaccination with genes encoding antigens GRA4 and SAG1 associated with GM-CSF plasmid, against acute, chronical and congenital toxoplasmosis in mice. Vaccine 2005, 23:4489-4499.
223. Mimura K.K., Tedesco R.C., Calabrese K.S., Gil C.D., Oliani S.M. The involvement of anti-inflammatory protein, annexin A1, in ocular toxoplasmosis. Mol. Vis. 2012, 18:1583-1593.
224. Minbaeva G., Schweiger A., Bodosheva A., Kuttubaev O., Hehl A.B., Tanner I., Ziadinov I., Torgerson P.R., Deplazes P. Toxoplasma gondii infection in Kyrgyzstan: seroprevalence, risk factor analysis, and estimate of congenital and AIDS-related toxoplasmosis. PLoS Negl. Trop. Dis. 2013, 7:e2043.
225. Miserocchi E., Modorati G., Rama P. Atypical toxoplasmosis masquerading late occurrence of typical findings. Eur. J. Ophthalmol. 2009, 19:1091-1093.
226. Mohamed R.M., Aosai F., Chen M., Mun H.S., Norose K., Belal U.S., Piao L.X., Yano A. Induction of protective immunity by DNA vaccination with Toxoplasma gondii HSP70, HSP30 and SAG1 genes. Vaccine 2003, 21:2852-2861.
227. Mohraz M., Mehrkhani F., Jam S., SeyedAlinaghi S., Sabzvari D., Fattahi F., Jabbari H., Hajiabdolbaghi M. Seroprevalence of toxoplasmosis in HIV(+)/AIDS patients in Iran. Acta Med. Iran. 2011, 49:213-218.
228. Montoya J.G., Remington J.S. Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. Clin. Infect. Dis. 1996, 23:277-282.
229. Montoya J.G., Liesenfeld O. Toxoplasmosis. Lancet 2004, 363:1965-1976.
230. Moraes A.M., Pessoa C.N., Vommaro R.C., De Souza W., de Mello F.G., Hokoc J.N. Cultured embryonic retina systems as a model for the study of underlying mechanisms of Toxoplasma gondii infection. Invest Ophthalmol. Vis. Sci. 2004, 45:2813-2821.
231. Morisset S., Peyron F., Lobry J.R., Garweg J., Ferrandiz J., Musset K., Gomez-Marin J.E., de la Torre A., Demar M., Carme B., Mercier C., Garin J.F., Cesbron-Delauw M.F. Serotyping of Toxoplasma gondii: striking homogeneous pattern between symptomatic and asymptomatic infections within Europe and South America. Microbes Infect. 2008, 10:742-747.
232. Munoz M., Liesenfeld O., Heimesaat M.M. Immunology of Toxoplasma gondii. Immunol. Rev. 2011, 240:269-285.
233. Nagamune K., Hicks L.M., Fux B., Brossier F., Chini E.N., Sibley L.D. Abscisic acid controls calcium-dependent egress and development in Toxoplasma gondii. Nature 2008, 451:207-210.
234. Nagineni C.N., Pardhasaradhi K., Martins M.C., Detrick B., Hooks J.J. Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infect. Immun. 1996, 64:4188-4196.
235. Nagineni C.N., Detrick B., Hooks J.J. Toxoplasma gondii infection induces gene expression and secretion of interleukin 1 (IL-1), IL-6, granulocyte-macrophage colony-stimulating factor, and intercellular adhesion molecule 1 by human retinal pigment epithelial cells. Infect. Immun. 2000, 68:407-410.
236. Nagineni C.N., Detrick B., Hooks J.J. Transforming growth factor-beta expression in human retinal pigment epithelial cells is enhanced by Toxoplasma gondii: a possible role in the immunopathogenesis of retinochoroiditis. Clin. Exp. Immunol. 2002, 128:372-378.
237. Nascimento L.V., Stollar F., Tavares L.B., Cavasini C.E., Maia I.L., Cordeiro J.A., Ferreira M.U. Risk factors for toxoplasmic encephalitis in HIV-infected patients: a case-control study in Brazil. Ann. Trop. Med. Parasitol. 2001, 95:587-593.
238. Neri P., Mercanti L., Mariotti C., Salvolini S., Giovannini A. Long-term control of choroidal neovascularization in quiescent congenital toxoplasma retinochoroiditis with photodynamic therapy: 4-year results. Int. Ophthalmol. 2010, 30:51-56.
239. Neto E.C., Anele E., Rubim R., Brites A., Schulte J., Becker D., Tuuminen T. High prevalence of congenital toxoplasmosis in Brazil estimated in a 3-year prospective neonatal screening study. Int. J. Epidemiol. 2000, 29:941-947.
240. Newman P.E., Ghosheh R., Tabbara K.F., O'Connor G.R., Stern W. The role of hypersensitivity reactions to toxoplasma antigens in experimental ocular toxoplasmosis in nonhuman primates. Am. J. Ophthalmol. 1982, 94:159-164.
241. Nicolle C. Sur une piroplasmose nouvelle d'un rongeur. CR Soc. Biol. 1907, 63:380-399.
242. Nicolle C., Manceaux L.H. On a leishman body infection (or related organisms) of the gondi. 1908. Int. J. Parasitol. 2009, 39:863-864.
243. Norose K., Mun H.S., Aosai F., Chen M., Piao L.X., Kobayashi M., Iwakura Y., Yano A. IFN-gamma-regulated Toxoplasma gondii distribution and load in the murine eye. Invest Ophthalmol. Vis. Sci. 2003, 44:4375-4381.
244. Norose K., Aosai F., Mizota A., Yamamoto S., Mun H.S., Yano A. Deterioration of visual function as examined by electroretinograms in Toxoplasma gondii-infected IFN-gamma-knockout mice. Invest Ophthalmol. Vis. Sci. 2005, 46:317-321.
245. Norose K., Kikumura A., Luster A.D., Hunter C.A., Harris T.H. CXCL10 is required to maintain T-cell populations and to control parasite replication during chronic ocular toxoplasmosis. Invest Ophthalmol. Vis. Sci. 2011, 52:389-398.
246. Nozik R.A., O'Connor G.R. Experimental toxoplasmic retinochoroiditis. Arch. Ophthalmol. 1968, 79:485-489.
247. Nozik R.A., O'Connor G.R. Studies on experimental ocular toxoplasmosis in the rabbit. II. Attempts to stimulate recurrences by local trauma, epinephrine, and corticosteroids. Arch. Ophthalmol. 1970, 84:788-791.
248. Nussenblatt R.B., Mittal K.K., Fuhrman S., Sharma S.D., Palestine A.G. Lymphocyte proliferative responses of patients with ocular toxoplasmosis to parasite and retinal antigens. Am. J. Ophthalmol. 1989, 107:632-641.
249. O'Connor G.R., Frenkel J.K. Editorial: dangers of steroid treatment in toxoplasmosis. Periocular injections and systemic therapy. Arch. Ophthalmol. 1976, 94:213.
250. O'Connor G.R. Factors related to the initiation and recurrence of uveitis. XL Edward Jackson memorial lecture. Am. J. Ophthalmol. 1983, 96:577-599.
251. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., Achkar J.P., Brant S.R., Bayless T.M., Kirschner B.S., Hanauer S.B., Nunez G., Cho J.H. Aframeshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
252. Ojo K.K., Larson E.T., Keyloun K.R., Castaneda L.J., Derocher A.E., Inampudi K.K., Kim J.E., Arakaki T.L., Murphy R.C., Zhang L., Napuli A.J., Maly D.J., Verlinde C.L., Buckner F.S., Parsons M., Hol W.G., Merritt E.A., Van Voorhis W.C. Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat. Struct. Mol. Biol. 2010, 17:602-607.
253. Olle P., Bessieres M.H., Malecaze F., Seguela J.P. The evolution of ocular toxoplasmosis in anti-interferon gamma treated mice. Curr. Eye Res. 1996, 15:701-707.
254. Opremcak E.M., Scales D.K., Sharpe M.R. Trimethoprim-sulfamethoxazole therapy for ocular toxoplasmosis. Ophthalmology 1992, 99:920-925.
255. Opsteegh M., Teunis P., Zuchner L., Koets A., Langelaar M., van der Giessen J. Low predictive value of seroprevalence of Toxoplasma gondii in cattle for detection of parasite DNA. Int. J. Parasitol. 2011, 41:343-354.
256. Pal R.A., Qayyum M., Yaseen M. Seroprevalence of antibodies to Toxoplasma gondii, with particular reference to obstetric history of patients in Rawalpindi-Islamabad, Pakistan. J.Pak Med. Assoc. 1996, 46:56-58.
257. Papadia M., Aldigeri R., Herbort C.P. The role of serology in active ocular toxoplasmosis. Int. Ophthalmol. 2011, 31:461-465.
258. Pappas G., Roussos N., Falagas M.E. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int. J. Parasitol. 2009, 39:1385-1394.
259. Paquet C., Yudin M.H. Toxoplasmosis in pregnancy: prevention, screening, and treatment. J.Obstet. Gynaecol. Can. 2013, 35:78-79.
260. Pavesio C.E., Chiappino M.L., Gormley P., Setzer P.Y., Nichols B.A. Acquired retinochoroiditis in hamsters inoculated with ME 49 strain Toxoplasma. Invest. Ophthalmol. Vis. Sci. 1995, 36:2166-2175.
261. Pearson P.A., Piracha A.R., Sen H.A., Jaffe G.J. Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology 1999, 106:148-153.
262. Peixoto-Rangel A.L., Miller E.N., Castellucci L., Jamieson S.E., Peixe R.G., Elias Lde S., Correa-Oliveira R., Bahia-Oliveira L.M., Blackwell J.M. Candidate gene analysis of ocular toxoplasmosis in Brazil: evidence for a role for toll-like receptor 9 (TLR9). Mem. Inst. Oswaldo Cruz 2009, 104:1187-1190.
263. Perkins E.S., Schofield P.B., Smith C.H. Treatment of uveitis with pyrimethamine (daraprim). Br. J. Ophthalmol. 1956, 40:577-586.
264. Peyron F., Lobry J.R., Musset K., Ferrandiz J., Gomez-Marin J.E., Petersen E., Meroni V., Rausher B., Mercier C., Picot S., Cesbron-Delauw M.F. Serotyping of Toxoplasma gondii in chronically infected pregnant women: predominance of type II in Europe and types I and III in Colombia (South America). Microbes Infect. 2006, 8:2333-2340.
265. Pfrepper K.I., Enders G., Gohl M., Krczal D., Hlobil H., Wassenberg D., Soutschek E. Seroreactivity to and avidity for recombinant antigens in toxoplasmosis. Clin. Diagn. Lab. Immunol. 2005, 12:977-982.
266. Phan L., Kasza K., Jalbrzikowski J., Noble A.G., Latkany P., Kuo A., Mieler W., Meyers S., Rabiah P., Boyer K., Swisher C., Mets M., Roizen N., Cezar S., Remington J., Meier P., McLeod R., Toxoplasmosis Study G. Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophthalmology 2008, 115:553-559. e558.
267. Phan L., Kasza K., Jalbrzikowski J., Noble A.G., Latkany P., Kuo A., Mieler W., Meyers S., Rabiah P., Boyer K., Swisher C., Mets M., Roizen N., Cezar S., Sautter M., Remington J., Meier P., McLeod R., Toxoplasmosis Study G. Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am. J. Ophthalmol. 2008, 146:375-384.
268. Pietkiewicz H., Hiszczynska-Sawicka E., Kur J., Petersen E., Nielsen H.V., Paul M., Stankiewicz M., Myjak P. Usefulness of Toxoplasma gondii recombinant antigens (GRA1, GRA7 and SAG1) in an immunoglobulin G avidity test for the serodiagnosis of toxoplasmosis. Parasitol. Res. 2007, 100:333-337.
269. Pivetti-Pezzi P., Accorinti M., La Cava M., Colabelli Gisoldi R.A., Abdulaziz M.A. Endogenous uveitis: an analysis of 1,417 cases. Ophthalmologica 1996, 210:234-238.
270. Pleyer U., Torun N., Liesenfeld O. Ocular toxoplasmosis. Ophthalmologe 2007, 104:603-615. Quiz 616.
271. Portela R.W., Bethony J., Costa M.I., Gazzinelli A., Vitor R.W., Hermeto F.M., Correa-Oliveira R., Gazzinelli R.T. Amultihousehold study reveals a positive correlation between age, severity of ocular toxoplasmosis, and levels of glycoinositolphospholipid-specific immunoglobulin A. J.Infect. Dis. 2004, 190:175-183.
272. Pusch L., Romeike B., Deckert M., Mawrin C. Persistent toxoplasma bradyzoite cysts in the brain: incidental finding in an immunocompetent patient without evidence of a toxoplasmosis. Clin. Neuropathol. 2009, 28:210-212.
273. Rajapakse S., Chrishan Shivanthan M., Samaranayake N., Rodrigo C., Deepika Fernando S. Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathog. Glob. Health 2013, 107:162-169.
274. Riss J.M., Carboni M.E., Franck J.Y., Mary C.J., Dumon H., Ridings B. Ocular toxoplasmosis: value of immunoblotting for the determination of an intra-ocular synthesis of antibodies. Pathol. Biol. (Paris) 1995, 43:772-778.
275. Robert-Gangneux F., Darde M.L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin. Microbiol. Rev. 2012, 25:264-296.
276. Roberts F., Mets M.B., Ferguson D.J., O'Grady R., O'Grady C., Thulliez P., Brezin A.P., McLeod R. Histopathological features of ocular toxoplasmosis in the fetus and infant. Arch. Ophthalmol. 2001, 119:51-58.
277. Rodriguez A. Photocoagulation in toxoplasmic retinochoroiditis. Am. J. Ophthalmol. 1981, 91:417-418.
278. Ronday M.J., Luyendijk L., Baarsma G.S., Bollemeijer J.G., Van der Lelij A., Rothova A. Presumed acquired ocular toxoplasmosis. Arch. Ophthalmol. 1995, 113:1524-1529.
279. Rosenthal B.M. How has agriculture influenced the geography and genetics of animal parasites?. Trends Parasitol. 2009, 25:67-70.
280. Rothova A., Meenken C., Buitenhuis H.J., Brinkman C.J., Baarsma G.S., Boen-Tan T.N., de Jong P.T., Klaassen-Broekema N., Schweitzer C.M., Timmerman Z., et al. Therapy for ocular toxoplasmosis. Am. J. Ophthalmol. 1993, 115:517-523.
281. Rothova A., Bosch-Driessen L.E., van Loon N.H., Treffers W.F. Azithromycin for ocular toxoplasmosis. Br. J. Ophthalmol. 1998, 82:1306-1308.
282. Rudich D.S., Bhatnagar P. Scleritis associated with toxoplasmic retinochoroiditis. Arch. Ophthalmol. 2012, 130:659-660.
283. Ruete C.G.T. Bildliche Darstellung der Krankheiten des menschlichen Auges: Physikalische Untersuchung des Auges 1854, vol. 1-2. Verlag von Teubner, Leipzig.
284. Ryan R., Hart W.M., Culligan J.J., Gunkel R.D., Jacobs L., Cook M.K. Diagnosis and treatment of toxoplasmic uveitis. Trans. Amer. Acad. Ophthal. Otolaryng. 1954, 58.
285. Sadaruddin A., Agha F., Anwar F., Ghafoor A. Seroepidemiology of Toxoplasma gondii infection in young school children in Islamabad. J.Pak. Med. Assoc. 1991, 41:131-134.
286. Saito M., Barbazetto I.A., Spaide R.F. Intravitreal cellular infiltrate imaged as punctate spots by spectral-domain optical coherence tomography in eyes with posterior segment inflammatory disease. Retina 2013, 33:559-565.
287. Sakikawa M., Noda S., Hanaoka M., Nakayama H., Hojo S., Kakinoki S., Nakata M., Yasuda T., Ikenoue T., Kojima T. Anti-Toxoplasma antibody prevalence, primary infection rate, and risk factors in a study of toxoplasmosis in 4,466 pregnant women in Japan. Clin. Vaccine Immunol. 2012, 19:365-367.
288. Sauer A., Pfaff A.W., Villard O., Creuzot-Garcher C., Dalle F., Chiquet C., Pelloux H., Speeg-Schatz C., Gaucher D., Prevost G., Bourcier T., Candolfi E. Interleukin 17A as an effective target for anti-inflammatory and antiparasitic treatment of toxoplasmic uveitis. J.Infect. Dis. 2012, 206:1319-1329.
289. Sauer A., Rochet E., Lahmar I., Brunet J., Sabou M., Bourcier T., Candolfi E., Pfaff A.W. The local immune response to intraocular Toxoplasma re-challenge: less pathology and better parasite control through Treg/Th1/Th2 induction. Int. J. Parasitol. 2013, 43:721-728.
290. Scharton-Kersten T.M., Yap G., Magram J., Sher A. Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii. J.Exp. Med. 1997, 185:1261-1273.
291. Schlüter D., Lohler J., Deckert M., Hof H., Schwendemann G. Toxoplasma encephalitis of immunocompetent and nude mice: immunohistochemical characterisation of Toxoplasma antigen, infiltrates and major histocompatibility complex gene products. J.Neuroimmunol. 1991, 31:185-198.
292. Schlüter D., Kwok L.Y., Lutjen S., Soltek S., Hoffmann S., Korner H., Deckert M. Both lymphotoxin-alpha and TNF are crucial for control of Toxoplasma gondii in the central nervous system. J.Immunol. 2003, 170:6172-6182.
293. Schuman J.S., Weinberg R.S., Ferry A.P., Guerry R.K. Toxoplasmic scleritis. Ophthalmology 1988, 95:1399-1403.
294. Scorza T., D'Souza S., Laloup M., Dewit J., De Braekeleer J., Verschueren H., Vercammen M., Huygen K., Jongert E. AGRA1 DNA vaccine primes cytolytic CD8(+) T cells to control acute Toxoplasma gondii infection. Infect. Immun. 2003, 71:309-316.
295. Sendi P., Sachers F., Drechsler H., Graber P. Immune recovery vitritis in an HIV patient with isolated toxoplasmic retinochoroiditis. AIDS 2006, 20:2237-2238.
296. Shaw M.H., Reimer T., Sanchez-Valdepenas C., Warner N., Kim Y.G., Fresno M., Nunez G. Tcell-intrinsic role of Nod2 in promoting type 1 immunity to Toxoplasma gondii. Nat. Immunol. 2009, 10:1267-1274.
297. Shen D.F., Matteson D.M., Tuaillon N., Suedekum B.K., Buggage R.R., Chan C.C. Involvement of apoptosis and interferon-gamma in murine toxoplasmosis. Invest Ophthalmol. Vis. Sci. 2001, 42:2031-2036.
298. Shobab L., Pleyer U., Johnsen J., Metzner S., James E.R., Torun N., Fay M.P., Liesenfeld O., Grigg M.E. Toxoplasma serotype is associated with development of ocular toxoplasmosis. J.Infect. Dis. 2013, 208:1520-1528.
299. Sibley L.D., Boothroyd J.C. Virulent strains of Toxoplasma gondii comprise a single clonal lineage. Nature 1992, 359:82-85.
300. Sibley L.D., Ajioka J.W. Population structure of Toxoplasma gondii: clonal expansion driven by infrequent recombination and selective sweeps. Annu. Rev. Microbiol. 2008, 62:329-351.
301. Siegel S.E., Lunde M.N., Gelderman A.H., Halterman R.H., Brown J.A., Levine A.S., Graw R.G. Transmission of toxoplasmosis by leukocyte transfusion. Blood 1971, 37:388-394.
302. Silva A.C., Rodrigues B.S., Micheletti A.M., Tostes S., Meneses A.C., Silva-Vergara M.L., Adad S.J. Neuropathology of AIDS: an autopsy review of 284 cases from Brazil comparing the findings pre- and Post-HAART (Highly active antiretroviral therapy) and pre- and Postmortem correlation. AIDS Res. Treat. 2012, 2012:186850.
303. Silveira C., Belfort R., Burnier M., Nussenblatt R. Acquired toxoplasmic infection as the cause of toxoplasmic retinochoroiditis in families. Am. J. Ophthalmol. 1988, 106:362-364.
304. Silveira C., Belfort R., Muccioli C., Abreu M.T., Martins M.C., Victora C., Nussenblatt R.B., Holland G.N. Afollow-up study of Toxoplasma gondii infection in southern Brazil. Am. J. Ophthalmol. 2001, 131:351-354.
305. Silveira C., Belfort R., Muccioli C., Holland G.N., Victora C.G., Horta B.L., Yu F., Nussenblatt R.B. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am. J. Ophthalmol. 2002, 134:41-46.
306. Silveira C., Vallochi A.L., Rodrigues da Silva U., Muccioli C., Holland G.N., Nussenblatt R.B., Belfort R., Rizzo L.V. Toxoplasma gondii in the peripheral blood of patients with acute and chronic toxoplasmosis. Br. J. Ophthalmol. 2011, 95:396-400.
307. Smith J.R., Cunningham E.T. Atypical presentations of ocular toxoplasmosis. Curr. Opin. Ophthalmol. 2002, 13:387-392.
308. Smith J.R., Franc D.T., Carter N.S., Zamora D., Planck S.R., Rosenbaum J.T. Susceptibility of retinal vascular endothelium to infection with Toxoplasma gondii tachyzoites. Invest Ophthalmol. Vis. Sci. 2004, 45:1157-1161.
309. Snider W.D., Simpson D.M., Nielsen S., Gold J.W., Metroka C.E., Posner J.B. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann. Neurol. 1983, 14:403-418.
310. Soheilian M., Ramezani A., Azimzadeh A., Sadoughi M.M., Dehghan M.H., Shahghadami R., Yaseri M., Peyman G.A. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology 2011, 118:134-141.
311. Solana R., Tarazona R., Gayoso I., Lesur O., Dupuis G., Fulop T. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin. Immunol. 2012, 24:331-341.
312. Sousa S., Ajzenberg D., Vilanova M., Costa J., Darde M.L. Use of GRA6-derived synthetic polymorphic peptides in an immunoenzymatic assay to serotype Toxoplasma gondii in human serum samples collected from three continents. Clin. Vaccine Immunol. 2008, 15:1380-1386.
313. Spalter H.F., Campbell C.J., Noyori K.S., Rittler M.C., Koester C.J. Prophylactic photocoagulation of recurrent toxoplasmic retinochoroiditis. A preliminary report. Arch. Ophthalmol. 1966, 75:21-31.
314. Stanford M.R., Tan H.-K., Gilbert R. Toxoplasmic retinochoroiditis presenting in childhood: clinical findings in a UK survey. Br. J. Ophthalmol. 2006, 90:1464-1467.
315. Strack A., Asensio V.C., Campbell I.L., Schlüter D., Deckert M. Chemokines are differentially expressed by astrocytes, microglia and inflammatory leukocytes in Toxoplasma encephalitis and critically regulated by interferon-gamma. Acta Neuropathol. 2002, 103:458-468.
316. Su C., Evans D., Cole R.H., Kissinger J.C., Ajioka J.W., Sibley L.D. Recent expansion of Toxoplasma through enhanced oral transmission. Science 2003, 299:414-416.
317. Subauste C. Animal models for Toxoplasma gondii infection. Curr. Protoc. Immunol. 2012, 13:11-23. (Chapter 19), Unit 19.
318. Subauste C.S., Koniaris A.H., Remington J.S. Murine CD8+ cytotoxic T lymphocytes lyse Toxoplasma gondii-infected cells. J.Immunol. 1991, 147:3955-3959.
319. Subauste C.S., Ajzenberg D., Kijlstra A. Review of the series "Disease of the year 2011: toxoplasmosis" pathophysiology of toxoplasmosis. Ocul. Immunol. Inflamm. 2011, 19:297-306.
320. Sugita S., Ogawa M., Inoue S., Shimizu N., Mochizuki M. Diagnosis of ocular toxoplasmosis by two polymerase chain reaction (PCR) examinations: qualitative multiplex and quantitative real-time. Jpn. J. Ophthalmol. 2011, 55:495-501.
321. Suzuki Y. Host resistance in the brain against Toxoplasma gondii. J.Infect. Dis. 2002, 185(Suppl.1):S58-S65.
322. Swai E.S., Schoonman L. Seroprevalence of Toxoplasma gondii infection amongst residents of Tanga district in north-east Tanzania. Tanzan J. Health Res. 2009, 11:205-209.
323. Tabbara K.F., Nozik R.A., O'Connor G.R. Clindamycin effects on experimental ocular toxoplasmosis in the rabbit. Arch. Ophthalmol. 1974, 92:244-247.
324. Tabbara K.F., O'Connor G.R. Ocular tissue absorption of clindamycin phosphate. Arch. Ophthalmol. 1975, 93:1180-1185.
325. Tabbara K.F., O'Connor G.R. Treatment of ocular toxoplasmosis with clindamycin and sulfadiazine. Ophthalmology 1980, 87:129-134.
326. Talabani H., Asseraf M., Yera H., Delair E., Ancelle T., Thulliez P., Brezin A.P., Dupouy-Camet J. Contributions of immunoblotting, real-time PCR, and the Goldmann-Witmer coefficient to diagnosis of atypical toxoplasmic retinochoroiditis. J.Clin. Microbiol. 2009, 47:2131-2135.
327. Talabani H., Mergey T., Yera H., Delair E., Brezin A.P., Langsley G., Dupouy-Camet J. Factors of occurrence of ocular toxoplasmosis. A review. Parasite 2010, 17:177-182.
328. Tenter A.M., Heckeroth A.R., Weiss L.M. Toxoplasma gondii: from animals to humans. Int. J. Parasitol. 2000, 30:1217-1258.
329. Thiébaut R., Leproust S., Chêne G., Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet 2007, 369:115-122.
330. Torgerson P.R., Mastroiacovo P. The global burden of congenital toxoplasmosis: a systematic review. Bull. World Health Organ 2013, 91:501-508.
331. Torun N., Sherif Z., Garweg J., Pleyer U. Diagnosis and treatment of ocular toxoplasmosis: a survey of German-speaking ophthalmologists. Ophthalmologe 2008, 105:1023-1028.
332. Uboldi de Capei M.U., Dametto E., Fasano M.E., Rendine S., Curtoni E.S. Genotyping for cytokine polymorphisms: allele frequencies in the Italian population. Eur. J. Immunogenet. 2003, 30:5-10.
333. Vallochi A.L., da Silva Rios L., Nakamura M.V., Silveira C., Muccioli C., Martins M.C., Belfort R., Rizzo L.V. The involvement of autoimmunity against retinal antigens in determining disease severity in toxoplasmosis. J.Autoimmun. 2005, 24:25-32.
334. Vallochi A.L., Muccioli C., Martins M.C., Silveira C., Belfort R., Rizzo L.V. The genotype of Toxoplasma gondii strains causing ocular toxoplasmosis in humans in Brazil. Am. J. Ophthalmol. 2005, 139:350-351.
335. Vasconcelos-Santos D.V. Ocular manifestations of systemic disease: toxoplasmosis. Curr. Opin. Ophthalmol. 2012, 23:543-550.
336. Villard O., Filisetti D., Roch-Deries F., Garweg J., Flament J., Candolfi E. Comparison of enzyme-linked immunosorbent assay, immunoblotting, and PCR for diagnosis of toxoplasmic chorioretinitis. J.Clin. Microbiol. 2003, 41:3537-3541.
337. Villena I., Ancelle T., Delmas C., Garcia P., Brezin A.P., Thulliez P., Wallon M., King L., Goulet V. Congenital toxoplasmosis in France in 2007: first results from a national surveillance system. Euro Surveill. 2010, 15.
338. Wallon M., Kodjikian L., Binquet C., Garweg J., Fleury J., Quantin C., Peyron F. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 2004, 113:1567-1572.
339. Walton B.C., Benchoff B.M., Brooks W.H. Comparison of the indirect fluorescent antibody test and methylene blue dye test for detection of antibodies to Toxoplasma gondii. Am. J. Trop. Med. Hyg. 1966, 15:149-152.
340. Walzer K.A., Boyle J.P. Asingle chromosome unexpectedly links highly divergent isolates of Toxoplasma gondii. MBio 2012, 3.
341. Weiss L.M., Kim K. The development and biology of bradyzoites of Toxoplasma gondii. Front. Biosci. 2000, 5:D391-D405.
342. Weiss L.M., Dubey J.P. Toxoplasmosis: a history of clinical observations. Int. J. Parasitol. 2009, 39:895-901.
343. Wendte J.M., Gibson A.K., Grigg M.E. Population genetics of Toxoplasma gondii: new perspectives from parasite genotypes in wildlife. Vet. Parasitol. 2011, 182:96-111.
344. Westeneng A.C., Rothova A., de Boer J.H., de Groot-Mijnes J.D. Infectious uveitis in immunocompromised patients and the diagnostic value of polymerase chain reaction and Goldmann-Witmer coefficient in aqueous analysis. Am. J. Ophthalmol. 2007, 144:781-785.
345. Wilder H.C. Toxoplasma chorioretinitis in adults; a preliminary study of forty-one cases diagnosed by microscopic examination. AMA Arch. Ophthalmol. 1952, 47:425.
346. Wilder H.C. Toxoplasma chorioretinitis in adults. AMA Arch. Ophthalmol. 1952, 48:127-136.
347. Wilson E.H., Wille-Reece U., Dzierszinski F., Hunter C.A. Acritical role for IL-10 in limiting inflammation during toxoplasmic encephalitis. J.Neuroimmunol. 2005, 165:63-74.
348. Wilson E.H., Harris T.H., Mrass P., John B., Tait E.D., Wu G.F., Pepper M., Wherry E.J., Dzierzinski F., Roos D., Haydon P.G., Laufer T.M., Weninger W., Hunter C.A. Behavior of parasite-specific effector CD8+ T cells in the brain and visualization of a kinesis-associated system of reticular fibers. Immunity 2009, 30:300-311.
349. Winterhalter S., Severing K., Stammen J., Maier A.K., Godehardt E., Joussen A.M. Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis?. Gr. Arch. Clin. Exp. Ophthalmol. 2010, 248:1187-1192.
350. Wolf A., Cowen D., Paige B. Human toxoplasmosis: occurrence in infants as an Encephalomyelitis verification by transmission to animals. Science 1939, 89:226-227.
351. Wu K., Chen X.G., Li H., Yan H., Yang P.L., Lun Z.R., Zhu X.Q. Diagnosis of human toxoplasmosis by using the recombinant truncated surface antigen 1 of Toxoplasma gondii. Diagn Microbiol. Infect. Dis. 2009, 64:261-266.
352. Wyler D.J., Blackman H.J., Lunde M.N. Cellular hypersensitivity to toxoplasmal and retinal antigens in patients with toxoplasmal retinochoroiditis. Am. J. Trop. Med. Hyg. 1980, 29:1181-1186.
353. Xavier G.A., Cademartori B.G., Cunha Filho N.A., Farias N.A. Evaluation of seroepidemiological toxoplasmosis in HIV/AIDS patients in the south of Brazil. Rev. Inst. Med. Trop. S. P. 2013, 55:25-30.
354. Yamamoto J.H., Vallochi A.L., Silveira C., Filho J.K., Nussenblatt R.B., Cunha-Neto E., Gazzinelli R.T., Belfort R., Rizzo L.V. Discrimination between patients with acquired toxoplasmosis and congenital toxoplasmosis on the basis of the immune response to parasite antigens. J.Infect. Dis. 2000, 181:2018-2022.
355. Yang P., Das P.K., Kijlstra A. Localization and characterization of immunocompetent cells in the human retina. Ocul. Immunol. Inflamm. 2000, 8:149-157.
356. Yuodelis C., Hendrickson A. Aqualitative and quantitative analysis of the human fovea during development. Vis. Res. 1986, 26:847-855.
357. Zamora D.O., Rosenbaum J.T., Smith J.R. Invasion of human retinal vascular endothelial cells by Toxoplasma gondii tachyzoites. Br. J. Ophthalmol. 2008, 92:852-855.
358. Zhou P., Chen Z., Li H.L., Zheng H., He S., Lin R.Q., Zhu X.Q. Toxoplasma gondii infection in humans in China. Parasit. Vectors 2011, 4:165.